SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT

The objective of the SCALE IBT trial (NCT02963935) was to compare the weight loss of liraglutide 3.0 mg, a medication approved by the Food and Drug Administration for chronic weight management, to placebo, both in combination with 56 weeks of intensive behavior therapy (IBT) (i.e. reduced calorie in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaw Tronieri, Jena, Wadden, Thomas, Sugimoto, Daniel, Lund, Michael, Auerbach, Pernille, Endahl, Lars, Rubino, Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552310/
http://dx.doi.org/10.1210/js.2019-SAT-097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552310/
http://dx.doi.org/10.1210/js.2019-SAT-097

Ejemplares similares